MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 561524 | Name: Medrogestone

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Medrogestone is a progestin that has been used in hormone replacement therapy for menopausal symptoms and in the treatment of gynecological disorders.

Chemical Structure

Medrogestone
Medrogestone
CAS#977-79-7

Theoretical Analysis

MedKoo Cat#: 561524

Name: Medrogestone

CAS#: 977-79-7

Chemical Formula: C23H32O2

Exact Mass: 340.2402

Molecular Weight: 340.50

Elemental Analysis: C, 81.13; H, 9.47; O, 9.40

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Medrogestone; Medrogesterone; AY-62022; R-13615; Prothil; Colpro;
IUPAC/Chemical Name
(8R,9S,10R,13S,14S,17S)-17-Acetyl-6,10,13,17-tetramethyl-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-3-one
InChi Key
HCFSGRMEEXUOSS-JXEXPEPMSA-N
InChi Code
InChI=1S/C23H32O2/c1-14-12-17-18(21(3)9-6-16(25)13-20(14)21)7-11-23(5)19(17)8-10-22(23,4)15(2)24/h12-13,17-19H,6-11H2,1-5H3/t17-,18+,19+,21-,22-,23+/m1/s1
SMILES Code
O=C1CC[C@]2(C)[C@@]3([H])CC[C@]4(C)[C@@](C)(C(C)=O)CC[C@@]4([H])[C@]3([H])C=C(C)C2=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 340.50 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Schindler AE. Dydrogesterone and other progestins in benign breast disease: an overview. Arch Gynecol Obstet. 2011 Feb;283(2):369-71. doi: 10.1007/s00404-010-1456-7. Epub 2010 Apr 11. Review. PubMed PMID: 20383772. 2: Pasqualini JR. Breast cancer and steroid metabolizing enzymes: the role of progestogens. Maturitas. 2009 Dec;65 Suppl 1:S17-21. doi: 10.1016/j.maturitas.2009.11.006. Epub 2009 Dec 3. Review. PubMed PMID: 19962254. 3: Pasqualini JR. Estrogen sulfotransferases in breast and endometrial cancers. Ann N Y Acad Sci. 2009 Feb;1155:88-98. doi: 10.1111/j.1749-6632.2009.04113.x. Review. PubMed PMID: 19250196. 4: Pasqualini JR. Progestins in the menopause in healthy women and breast cancer patients. Maturitas. 2009 Apr 20;62(4):343-8. doi: 10.1016/j.maturitas.2008.12.008. Review. PubMed PMID: 19179024. 5: Pasqualini JR. Progestins and breast cancer. Gynecol Endocrinol. 2007 Oct;23 Suppl 1:32-41. Review. PubMed PMID: 17943537. 6: Pasqualini JR, Chetrite GS. Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer. J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):221-36. Review. PubMed PMID: 15860265. 7: Pasqualini JR. The selective estrogen enzyme modulators in breast cancer: a review. Biochim Biophys Acta. 2004 Jun 7;1654(2):123-43. Review. PubMed PMID: 15172700. 8: Pasqualini JR. Differential effects of progestins on breast tissue enzymes. Maturitas. 2003 Dec 10;46 Suppl 1:S45-54. Review. PubMed PMID: 14670645. 9: Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, Thijssen JH. Classification and pharmacology of progestins. Maturitas. 2003 Dec 10;46 Suppl 1:S7-S16. Review. PubMed PMID: 14670641. 10: Schneider HP. Androgens and antiandrogens. Ann N Y Acad Sci. 2003 Nov;997:292-306. Review. PubMed PMID: 14644837. 11: Jamin C, Poncelet C, Madelenat P. [Tibolone]. Presse Med. 2002 Sep 7;31(28):1314-22. Review. French. PubMed PMID: 12355994. 12: Pasqualini JR, Ebert C. Biological effects of progestins in breast cancer. Gynecol Endocrinol. 1999 Jun;13 Suppl 4:11-9. Review. PubMed PMID: 12227897. 13: Pasqualini JR, Ebert C, Chetrite GS. Biological effects of progestins in breast cancer. Gynecol Endocrinol. 2001 Dec;15 Suppl 6:44-52. Review. PubMed PMID: 12227886. 14: Chetrite GS, Pasqualini JR. The selective estrogen enzyme modulator (SEEM) in breast cancer. J Steroid Biochem Mol Biol. 2001 Jan-Mar;76(1-5):95-104. Review. PubMed PMID: 11384867. 15: Pasqualini JR, Ebert C, Chetrite GS. The SEEM: selective estrogen enzyme modulators in breast cancer. Gynecol Endocrinol. 1999 Dec;13 Suppl 6:1-8. Review. PubMed PMID: 10862262. 16: Egarter C, Geurts P, Boschitsch E, Speiser P, Huber J. The effects of estradiol valerate plus medroxyprogesterone acetate and conjugated estrogens plus medrogestone on climacteric symptoms and metabolic variables in perimenopausal women. Acta Obstet Gynecol Scand. 1996 Apr;75(4):386-93. Review. PubMed PMID: 8638462. 17: Birkhäuser M. Hormone replacement therapy and estrogen-dependent cancers. Int J Fertil Menopausal Stud. 1994;39 Suppl 2:99-114. Review. PubMed PMID: 7874193. 18: Heckers H, Platt D. [Lipoprotein metabolism in menopause. Effect of hormonal substitution therapy]. Fortschr Med. 1991 Jun 20;109(18):379-82. Review. German. PubMed PMID: 1916555. 19: Lauritzen C. Clinical use of oestrogens and progestogens. Maturitas. 1990 Sep;12(3):199-214. Review. PubMed PMID: 2215269. 20: Baird DT, West CP. Medical management of fibroids. Br Med J (Clin Res Ed). 1988 Jun 18;296(6638):1684-5. Review. PubMed PMID: 3135875; PubMed Central PMCID: PMC2546081.